Laboratoires Thea

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Laboratoires Thea sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 4 completed early-phase tilt top decile by trial count

Laboratoires Thea: 11 sponsored US clinical trials, 2 recruiting.

Laboratoires Thea sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 2 trials.

Top-decile sponsor footprint

Laboratoires Thea ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443
RECRUITING Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179
ACTIVE NOT RECRUITING Phase 1

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267
COMPLETED Phase 2

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT06394973
COMPLETED Phase 1

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

NCT05729594
COMPLETED Phase 3

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

NCT05397600
TERMINATED Phase 2

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

NCT05176717
TERMINATED Phase 2

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

NCT05158296
TERMINATED Phase 2

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

NCT05085964
TERMINATED Phase 1

Extension Study to Study PQ-110-001 (NCT03140969)

NCT03913130
COMPLETED Phase 1

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

NCT03140969

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 2

Therapeutic Areas

Ocular Hypertension 2
Glaucoma 2
Retinal Disease 2
Eye Disorders Congenital 2
Eye Diseases, Hereditary 2
Vision Disorders 1
Deaf Blind 1
Usher Syndrome Type 2 1
Retinitis Pigmentosa (RP) 1
Neurological Manifestations 1

What is open in the Laboratoires Thea pipeline

2 recruiting of 11 indexed (18% open); 4 completed (36%).

Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Ocular Hypertension (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Laboratoires Thea: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Laboratoires Thea sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share Laboratoires TheaAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
Laboratoires Thea sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Laboratoires Thea sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Laboratoires Thea page

11 registered trials is a research-attention snapshot, not an endorsement of Laboratoires Thea or any single study.

  • 2 of Laboratoires Thea's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Ocular Hypertension is the condition Laboratoires Thea studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Laboratoires Thea pipeline card: 11 registered trials from official public datasets.Report a data error.